Related Experiment Video

Updated: Jul 20, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

[Is MDR 1 gene a key to successful chemotherapy?]

Jacek R Wilczyński1, Maja Kufelnicka, Beata Smolarz

  • 1III Katedra Połoznictwa i Ginekologii UM w Lodzi. jrwil@post.pl

Ginekologia Polska
|September 13, 2006
PubMed

Insights

Pharmacogenetics helps personalize cancer chemotherapy by analyzing multidrug resistance genes. Genotyping these genes, like MDR1, can predict patient response to chemotherapy drugs.

Area of Science:

  • Oncology
  • Pharmacogenetics
  • Molecular Biology

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy, reducing treatment efficacy.
  • Disturbed trans-membrane transport of chemotherapeutics, influenced by drug resistance gene expression (e.g., MRP1, LRP, BCRP), is a key mechanism of chemo-resistance.
  • Polymorphisms in the MDR1 gene, encoding P-glycoprotein (P-gp), are implicated in varied responses to chemotherapy drugs.

Purpose of the Study:

  • To explore the role of pharmacogenetics in overcoming multidrug resistance in oncology.
  • To investigate how MDR1 gene polymorphisms affect patient outcomes in chemotherapy.
  • To assess the potential of genotyping multidrug resistance genes for predicting chemotherapy sensitivity.

Main Methods:

  • Review of current literature on pharmacogenetics and multidrug resistance in cancer therapy.
  • Analysis of studies focusing on MDR1 gene polymorphisms and their association with treatment outcomes.
  • Examination of specific chemotherapy drugs affected by P-gp transport, including digoxin, fexofenadine, etoposide, vincristine, vinblastine, anthracyclines, and taxanes.

Main Results:

  • Pharmacogenetic approaches are increasingly used in oncology for personalized patient treatment.
  • MDR1 gene polymorphisms significantly influence the efficacy of various chemotherapy agents.
  • Genotyping multidrug resistance genes and identifying haplotypes show promise in predicting individual responses to chemotherapy.

Conclusions:

  • Pharmacogenetics offers a pathway to improve chemotherapy efficacy through individualized treatment strategies.
  • Understanding MDR1 gene variations is crucial for predicting patient response to a range of chemotherapeutic drugs.
  • Genotyping drug resistance genes represents a valuable tool for tailoring chemotherapy regimens and improving patient outcomes.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...